Fact check
Is it true: Repatha and Statin Suppression Claims?
No — this has been debunked.
Repatha (evolocumab) is FDA-approved, WHO-listed, and generated approximately $1.7 billion in Amgen revenue in 2023. Its pivotal trials (FOURIER, ODYSSEY OUTCOMES) are published in the New England Journal of Medicine. Statins remain first-line because they are off-patent, inexpensive ($4–10/month generic), and have a large independent evidence base — not because PCSK9 inhibitors are suppressed. The Repatha suppression framing has no documentary basis. Known statin adverse effects (myopathy, modest diabetes risk increase) are documented in labeling and mainstream literature.
The claim
Claims circulate that pharmaceutical companies or medical institutions suppress Repatha (evolocumab, a PCSK9 inhibitor approved by the FDA in 2015) or effective alternatives to statins. The claim has
Key evidence
Repatha is FDA-approved and actively marketed
Conspirafy steelmans each claim, then follows the evidence. How we reach a verdict · Check another claim